AUTL - オ―トルス・セラピュ―ティクス (Autolus Therapeutics plc) オ―トルス・セラピュ―ティクス

 AUTLのチャート


 AUTLの企業情報

symbol AUTL
会社名 Autolus Therapeutics PLC (オ―トルス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Autolus Therapeutics plc formerly Autolus Therapeutics Limited is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company''s clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2 AUTO3 AUTO4 and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.   オ―トルス・セラピュ―ティクスはイギリスのバイオ医薬品企業。主にがん治療に対する次世代のT細胞療法の開発に従事する。同社は独自のモジュ―ル型T細胞プログラミング技術を使用して、より正確にがん細胞を認識し、防御機能を破壊して、がん細胞を排除するより活性的なT細胞療法を開発する。本社所在地はロンドン。   
本社所在地 Forest House 58 Wood Lane London W12 7RZ GBR
代表者氏名
代表者役職名
電話番号 +44 20-3829-6230
設立年月日 43132
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 126人
url www.autolus.com
nasdaq_url https://www.nasdaq.com/symbol/autl
adr_tso 10147059
EBITDA EBITDA(百万ドル) ー
終値(lastsale) 28.01
時価総額(marketcap) 284219122.59
時価総額 時価総額(百万ドル) 151.882
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) ー
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the fiscal year ended 30 September 2017 Autolus Therapeutics Ltd - ADR revenues increased 40% to $1.7M. Net loss increased 57% to $19.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 56% to $14.9M (expense) General and administrative - Balancing v increase of 86% to $7.1M (expense).

 AUTLのテクニカル分析


 AUTLのニュース

   Autolus Therapeutics Raises $100M Via Equity  2021/02/10 06:59:00 Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares …
   Autolus Announces Pricing of Public Offering  2021/02/09 20:42:00 Benzinga
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation …
   Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting - Stocks News Feed  2020/12/05 20:01:00 Stocks News Feed
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec. 05, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell… Read More »Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
   Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Stocks News Feed  2020/11/17 12:00:00 Stocks News Feed
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking… Read More »Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference
   Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post Quarterly Sales of $310,000.00  2020/10/25 02:36:42 US Banking News
Wall Street brokerages predict that Autolus Therapeutics plc (NASDAQ:AUTL) will report sales of $310,000.00 for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Autolus Therapeutics’ earnings. The highest sales estimate is $340,000.00 and the lowest is $290,000.00. Autolus Therapeutics posted sales of $300,000.00 during the same quarter last year, which would […]
   Autolus Therapeutics Raises $100M Via Equity  2021/02/10 06:59:00 Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares …
   Autolus Announces Pricing of Public Offering  2021/02/09 20:42:00 Benzinga
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation …
   Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting - Stocks News Feed  2020/12/05 20:01:00 Stocks News Feed
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec. 05, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell… Read More »Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
   Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Stocks News Feed  2020/11/17 12:00:00 Stocks News Feed
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking… Read More »Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference
   Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post Quarterly Sales of $310,000.00  2020/10/25 02:36:42 US Banking News
Wall Street brokerages predict that Autolus Therapeutics plc (NASDAQ:AUTL) will report sales of $310,000.00 for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Autolus Therapeutics’ earnings. The highest sales estimate is $340,000.00 and the lowest is $290,000.00. Autolus Therapeutics posted sales of $300,000.00 during the same quarter last year, which would […]
   Autolus Therapeutics Raises $100M Via Equity  2021/02/10 06:59:00 Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares …
   Autolus Announces Pricing of Public Offering  2021/02/09 20:42:00 Benzinga
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation …
   Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting - Stocks News Feed  2020/12/05 20:01:00 Stocks News Feed
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec. 05, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell… Read More »Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
   Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Stocks News Feed  2020/11/17 12:00:00 Stocks News Feed
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking… Read More »Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference
   Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post Quarterly Sales of $310,000.00  2020/10/25 02:36:42 US Banking News
Wall Street brokerages predict that Autolus Therapeutics plc (NASDAQ:AUTL) will report sales of $310,000.00 for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Autolus Therapeutics’ earnings. The highest sales estimate is $340,000.00 and the lowest is $290,000.00. Autolus Therapeutics posted sales of $300,000.00 during the same quarter last year, which would […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―トルス・セラピュ―ティクス AUTL Autolus Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)